Skip to main content

Table 2 Patient characteristics

From: Physical activity assessment by accelerometry in people with heart failure

Characteristic

N = 22 patients Mean ± SD unless otherwise stated

Male (n, %)

17 (77)

Age (years)

70.7 ± 14.1

Body Mass Index (kg/m2)

28.1 ± 4.4

LVEF (%)

34.5 ± 14.0

Reduced LVEF < 40% (n, %)

14 (64)

Mid-range LVEF 40–49% (n, %)

4 (18)

Preserved EF ≥50% (n, %)

4 (18)

NYHA class (n, %)

 I

1 (4)

 II

18 (82)

 III

3 (14)

 IV

0

Dilated cardiomyopathy (n, %)

14 (64)

Ischaemic heart disease (n, %)

8 (36)

ICD/CRT/Pacemaker (n, %)

13 (59)

ACE-I/ARB/ARNI (n, %)

21 (95)

Beta-blocker (n, %)

22 (100)

MRA (n, %)

14 (64)

Loop diuretic (n, %)

17 (77)

Hypertension (n, %)

11 (50)

Diabetes (n, %)

6 (27)

COPD (n, %)

4 (18)

Arthritis (n, %)

2 (9)

AF (n, %)

11 (50)

Stroke (n, %)

5 (23)

Comorbidities (hypertension, diabetes, COPD, arthritis, AF, stroke) (n, %)

 0 comorbidity

6 (27)

 1 comorbidity

4 (18)

 2 comorbidities

5 (23)

 3 comorbidities

4 (18)

 4+ comorbidities

3 (14)

ISWT distance (m)

286.4 ± 190.6

RMR (mL O2·kg−1·min−1)

2.67 ± 0.66

  1. Data presented as mean ± standard deviation or as number (percentage). LVEF left ventricular ejection fraction, NYHA New York Heart Association, ICD implantable cardioverter defibrillator, CRT cardiac resynchronisation therapy, ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, ARNI angiotensin II receptor blocker neprilysin inhibitor, MRA mineralocorticoid receptor antagonist, COPD chronic obstructive pulmonary disease, AF atrial fibrillation, ISWT incremental shuttle walk test